Comparison of Efficacy and Safety Outcomes of Different Doses Schedules of Thalidomide for Treating Moderate-to-Severe f-Thalassemia Patients

被引:0
作者
Yang, Wei-Jia [1 ,7 ]
Shi, Lian-dong [2 ]
Liang, Ye [3 ,4 ]
Liang, Li-ming [5 ]
Zhang, Hao [6 ]
Wang, Li [2 ]
Zhou, Qian [1 ]
机构
[1] Guilin Peoples Hosp, Dept Eugen & Genet, 12 Wenming Rd, Guilin 541002, Guangxi Zhuang, Peoples R China
[2] Guilin Peoples Hosp, Dept Ultrasound, Guilin 541002, Guangxi Zhuang, Peoples R China
[3] Peoples Hosp Guangxi Zhuang Autonomous Reg, Guangxi Acad Med Sci, Dept Cardiol, Nanning 530000, Peoples R China
[4] Guangxi Acad Med Sci, Inst Cardiovasc Dis, Nanning 530000, Peoples R China
[5] Guilin Women & Childrens Hosp, Dept Genet Metab Ctr Lab, Guilin 541001, Guangxi Zhuang, Peoples R China
[6] Guilin Peoples Hosp, Dept Pharm, Guilin 541002, Guangxi Zhuang, Peoples R China
[7] Guilin Peoples Hosp, Dept Eugen & Genet, 12 Wenming Rd, Guilin 541002, Guangxi Zhuang, Peoples R China
关键词
f; -thalassemia; clinical efficacy; safety; thalidomide; LONG-TERM;
D O I
10.2147/TCRM.S481128
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: In this study, we evaluated the effectiveness and safety of thalidomide by clinically observing 48 individuals with f thalassemia who have been administered thalidomide in small and medium doses over a period of two years. Methods: Thalidomide's efficacy was gauged by tracking hemoglobin (Hb) level alterations post its administration. Liver and kidney function impact was measured through tests for alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, and creatinine. Hemolysis effects were assessed via total bilirubin and indirect bilirubin level measurements. Thrombosis detection was performed using ultrasound examinations of deep vein vessels in the upper and lower extremities. Any adverse effects of thalidomide were recorded during the observation period. Lower dose thalidomide effectiveness was evaluated by monitoring Hb level changes following dosage reduction. Results: The overall response rate (ORR) among the 48 participants was 91.7% (44 out of 48), with the main reaction (MaR) reaching 72.9% (35 out of 48). Hepatorenal toxicity was not monitored during the 2-year observation period, and there was no improvement in hemolysis. Most adverse effects were mild, with no instances of venous thrombosis and no cases of grade 2 or higher neurotoxicity. When the observation group was divided into three age categories (12-14 years old, 14-18 years old, and over 18 years old), there were no statistically significant differences in the occurrence of adverse reactions among the three groups. As there were some adverse reactions in ten cases, the treatment dose was reduced for them. The maintenance efficacy rate at one year of observation was 90% (9 Conclusion: This study confirmed that thalidomide in small doses over a 2-year observation period is effective, and has no instances of grade 2 or higher neurotoxicity. Long-term maintenance with small doses is recommended for enhanced safety.
引用
收藏
页码:799 / 809
页数:11
相关论文
共 19 条
[1]   Thalidomide induces γ-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis [J].
Aerbajinai, Wulin ;
Zhu, Jianqiong ;
Gao, Zhigang ;
Chin, Kyung ;
Rodgers, Griffin P. .
BLOOD, 2007, 110 (08) :2864-2871
[2]   Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent β-thalassemia: results from Thal-Thalido study [J].
Ali, Zahid ;
Ismail, Mohammad ;
Ur Rehman, Inayat ;
Rani, Gulab Fatima ;
Ali, Muhammad ;
Khan, Muhammad Tariq Masood .
SCIENTIFIC REPORTS, 2023, 13 (01)
[3]  
[Anonymous], COMMON TERMINOLOGY C
[4]   Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia [J].
Barcellini, W. ;
Fattizzo, B. .
DISEASE MARKERS, 2015, 2015
[5]  
Beijing Angel Mom Charity Foundation & Beijing Normal University China Philanthropy Research Institute, 2021, China thalassemia blue book: report on the prevention and treatment of thalassemia in China
[6]   Efficacy and Safety of Thalidomide in Patients With Transfusion-Dependent Thalassemia [J].
Chandra, Jagdish ;
Parakh, Nupur ;
Sidharth ;
Singh, Neha ;
Sharma, Sunita ;
Goel, Manish ;
Pemde, Harish .
INDIAN PEDIATRICS, 2021, 58 (07) :611-616
[7]  
Dong B Q, 2019, Zhonghua Liu Xing Bing Xue Za Zhi, V40, P1554, DOI 10.3760/cma.j.issn.0254-6450.2019.12.009
[8]  
Eleftheriou A, 2021, Global thalassaemia review 2021
[9]  
Guangdong Association for the Prevention and Treatment of (3-thalassemia Editorial Committee of Chinese Journal of Practical Pediatrics, 2018, Chinese J Practical Pediatr, V33, P929
[10]   Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia-a pilot study from a tertiary care Centre of India [J].
Jain, Manisha ;
Chakrabarti, Prantar ;
Dolai, Tuphan Kanti ;
Ghosh, Pramit ;
Mandal, Prakas Kumar ;
Baul, Shuvra Neel ;
De, Rajib .
BLOOD CELLS MOLECULES AND DISEASES, 2021, 88